|
1) Kelley WN, et al. Clinical features of SLE. In: Textbook of Rheumatology. Philadelphia: WB Saunders; 2000
|
|
|
|
|
2) Weening JJ, D'Agati VD, Schwartz MM, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int. 2004; 65: 521-30
|
|
|
|
|
3) Appel GB, Cohen DJ, Pirani CL, et al. Long-term follow-up of patients with lupus nephritis. A study based on the classification of the World Health Organization. Am J Med. 1987; 83: 877-85
|
|
|
|
|
|
4) Schwartz MM, Lan SP, Bonsib SM, et al. Clinical outcome of three discrete histologic patterns of injury in severe lupus glomerulonephritis. Am J Kidney Dis. 1989; 13: 273-83
|
|
|
|
|
|
5) Kojo S, Sada KE, Kobayashi M, et al. Clinical usefulness of a prognostic score in histological analysis of renal biopsy in patients with lupus nephriti. J Rheumatol. 2009; 36: 2218-23
|
|
|
|
|
|
6) Donadio JV Jr, Burgess JH, Holley KE, et al. Membranous lupus nephropathy: a clinicopathologic study. Medicine (Baltimore). 1977; 56: 527-36
|
|
|
|
|
|
7) Kobert SM, et al. Lupus Nephritis Collaborative Study Group: Factors predictive of outcome in severe lupus nephritis. Am J Kidney Dis. 2000; 35: 904-14
|
|
|
|
|
|
8) Gourley MF, Austin HA, Scott D, et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med. 1996; 125: 549-57
|
|
|
|
|
|
9) Illei GG, Austin HA, Crane M, et al. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med. 2001; 135: 248-57
|
|
|
|
|
|
10) Kamanamool N, McEvoy M, Attia J, et al. Efficacy and adverse events of mycophenolate mofetil versus cyclophosphamide for induction therapy of lupus nephritis. Medicine. 2010; 89: 227-35
|
|
|
|
|
|
11) Bao H, Liu ZH, Xie HL, et al. Successful treatment of class V＋IV lupus nephritis with multitarget therapy. J Am Soc Nephrol. 2008; 19: 2001-10
|
|
|
|
|
|
12) Tanaka H, Tsugawa K, Oki E, et al. Mizoribine intermittent pulse protocol for induction therapy for systemic lupus erythematosus in children: an open-label pilot stude with five newly diagnosed patients. Clinical Rheumatology. 2008; 27: 85-9
|
|
|
|
|
|
13) Contreras G, Pardo V, Leclercq B, et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med. 2004; 350: 971-80
|
|
|
|
|
|
14) Press release: CellCept® reaches positive results in Phase III trial in Lupus Nephritis. Galenica. 2010. http: //www. galenica. com/en/medien/medienmitteilungen/2010/20100603_543877196_meldung. php
|
|
|
|
|
|
15) Yumura W, Suganuma S, Uchida K, et al. Effects of longterm treatment with mizoribine in patients with proliferative lupus nephritis. Clinical Nephrology. 2005; 64: 28-34
|
|
|
|
|